Etanercept versus etanercept plus methotrexate: a registry-based study suggesting that the combination is clinically more efficacious
Etanercept versus etanercept plus methotrexate: a registry-based study suggesting that the combination is clinically more efficacious
复制标题
DOI：
10.1186/ar1005
复制
发表时间：
2003-01-01
影响因子：
4.9
通讯作者：
Klareskog, L
中科院分区：
文献类型：
--
作者：
van Vollenhoven, RF;Ernestam, S;Klareskog, L
依那西普既可以作为单一疗法使用，也可以与甲氨蝶呤 (MTX) 联合使用，但尚未报道这两种选择的直接比较。为了比较这两种选择在实际实践中看到的结果，对斯德哥尔摩 TNFalpha 随访登记处跟踪的 97 名患者的临床数据进行了分析。其中 57 名患者在之前开始使用的 MTX 中添加了依那西普，而其他患者则单独接受依那西普治疗。两组的基线疾病活动水平相似。 3 个月后，接受依那西普加 MTX 治疗的患者获得了显着较低的平均疾病活动评分（基于 28 个关节计数的疾病活动评分）。在该组中，达到欧洲抗风湿病联盟定义的缓解的患者数量也显着增加。其他疾病结果显示出相同方向的非显着趋势。这些数据表明，依那西普加 MTX 的组合在临床上比单独使用依那西普更有效。
Etanercept can be used both as monotherapy and in combination with methotrexate (MTX), but direct comparisons of these two options have not yet been reported. In order to compare the results seen in actual practice between these two options, clinical data on 97 patients followed in the Stockholm TNFalpha Follow-Up Registry were analysed. In 57 of these patients etanercept was added to previously started MTX while the others were treated with etanercept alone. The two groups had similar levels of disease activity at baseline. After 3 months, a significantly lower mean disease activity score (28-joint count-based disease activity score) was attained by the patients on etanercept plus MTX. In this group, the number of patients achieving European League Against Rheumatism-defined remission was also significantly greater. Other disease outcomes showed non-significant trends in the same direction. These data suggest that the combination of etanercept plus MTX is clinically more efficacious than etanercept alone.